CEL-SCI Corporation (NYSE:CVM) has continued to generate data and analysis related to its IT-MATTERS trial - a Phase III study evaluating Multikine in advanced primary squamous cell carcinoma of ...

CEL-SCI Corporation (NYSE:CVM) provided several updates in recent weeks. This includes details from its pre-submission meeting with the FDA, a poster presentation related to Multikine performance ...